Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
Mangaonkar AA, Langer KJ, Lasho TL, Finke C, Litzow MR, Hogan WJ, Shah MV, Go RS, Bartoo G, Kutzke J, McCullough KB, Koster M, Samec M, Warrington KJ, Reichard KK, Olteanu H, Riwes M, Patnaik MM, Alkhateeb HB. Mangaonkar AA, et al. Am J Hematol. 2023 Feb;98(2):E28-E31. doi: 10.1002/ajh.26786. Epub 2022 Dec 1. Am J Hematol. 2023. PMID: 36403135 Free article. No abstract available.
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis.
Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, Reichard K, Ketterling R, Gangat N, Xie Z, Fernandez J, Chia N, Gaspar-Maia A, Binder M, Patnaik MM. Lasho T, et al. Among authors: mangaonkar a. Leukemia. 2023 Jun;37(6):1384-1387. doi: 10.1038/s41375-023-01887-z. Epub 2023 Mar 25. Leukemia. 2023. PMID: 36966263 No abstract available.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. Hiwase D, et al. Among authors: mangaonkar a. Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236. Blood. 2023. PMID: 36574363 Free article. No abstract available.
Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings.
Hines AS, Mohandesi NA, Lehman JS, Koster MJ, Cantwell HM, Alavi A, Warrington KJ, Mangaonkar AA, Go RS, Patnaik MM, Sartori-Valinotti JC. Hines AS, et al. Among authors: mangaonkar aa. Int J Dermatol. 2023 Jul;62(7):938-945. doi: 10.1111/ijd.16635. Epub 2023 Mar 8. Int J Dermatol. 2023. PMID: 36890121
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Abdallah M, McCullough K, Ilyas R, Begna KH, Al-Kali A, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Yi CA, Sproat L, Pardanani A, Patnaik MM, Olteanu H, Ketterling RP, Tefferi A, Gangat N. Abdallah M, et al. Among authors: mangaonkar a. Blood Cancer J. 2023 Mar 13;13(1):35. doi: 10.1038/s41408-023-00812-y. Blood Cancer J. 2023. PMID: 36907917 Free PMC article. No abstract available.
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: mangaonkar a. Blood Adv. 2023 Apr 25;7(8):1351-1355. doi: 10.1182/bloodadvances.2022007937. Blood Adv. 2023. PMID: 36477202 Free PMC article. No abstract available.
133 results